Market Alert: Global Markets May Rebound Amid Signs of U.S. Economic Resilience
Memphasys Limited (ASX: MEM) has strengthened its position in Japan’s fertility market with a repeat order for 200 Felix cartridges, valued at AU$24,000, from the Nishitan ART Clinic Kobe Sannomiya Branch. Part of Japan’s leading fertility network, Nishitan ART Clinic Group conducts around 21,000 IVF/ICSI cycles annually. The new order marks Felix’s transition to repeat clinical use and supports Memphasys’ new go-direct commercial strategy in Japan. The company plans to engage directly with the Kobe clinic and the broader Nishitan network to expand adoption, build clinical advocacy, and generate local reference data.
With Japan performing nearly 500,000 IVF cycles annually—20% of which fall within the premium self-pay segment—Memphasys sees significant potential for Felix as a high-quality, evidence-based sperm selection technology. CEO Dr. David Ali said growing clinician confidence is expected to drive continued momentum into FY2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Oct 24, 2025
Oct 24, 2025
Oct 24, 2025
Oct 24, 2025
Oct 24, 2025
Oct 24, 2025
Oct 24, 2025
Oct 24, 2025
Oct 24, 2025
Oct 24, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.